Fractional kill

Last updated

In oncology, the fact that one round of chemotherapy does not kill all the cells in a tumor is a poorly understood phenomenon called fractional kill, or fractional cell kill.

Contents

The fractional kill hypothesis states that a defined chemotherapy concentration, applied for a defined time period, will kill a constant fraction of the cells in a population, independent of the absolute number of cells. [1] [2] [3] In solid tumors, poor access of the tumor to the drug can limit the fraction of tumor cells killed, but the validity of the fractional kill hypothesis has also been established in animal models of leukemia, as well as in human leukemia and lymphoma, where drug access is less of an issue. [3]

Because only a fraction of the cells die with each treatment, repeated doses must be administered to continue to reduce the size of the tumor. [4] Current chemotherapy regimens apply drug treatment in cycles, with the frequency and duration of treatments limited by toxicity to the patient. [3] The goal is to reduce the tumor population to zero with successive fractional kills. [3] For example, assuming a 99% kill per cycle of chemotherapy, a tumor of 1011 cells would be reduced to less than one cell with six treatment cycles: 1011 * 0.016 < 1. [3] However, the tumor can also re-grow during the intervals between treatments, limiting the net reduction of each fractional kill. [4]

Cited cause of fractional killing: cell cycle effects

The fractional killing of tumors in response to treatment is assumed to be due to the cell cycle specificity of chemotherapy drugs. [3] [4] Cytarabine, a DNA-synthesis inhibitor also known as ara-C, is cited as the classic cell cycle phase-specific agent. [4] Chemotherapy dosing schedules have been optimized based on the fact that cytarabine is only expected to be effective in the DNA synthesis (S) phase of the cell cycle. [4] Consistent with this, leukemia patients respond better to cytarabine treatments given every 12 hours rather than every 24 hours. This finding that can be explained by the fact that S-phase in these leukemia cells lasts 18–20 hours, allowing some cells to escape the cytotoxic effect of the drug if it is given every 24 hours. [4] However, alternative explanations are possible, as described below.

Lack of cell cycle effect in drugs documented to be cell cycle phase specific

Very little direct information is available on whether cells undergo apoptosis from a certain point in the cell cycle. [5] One study which did address this topic used flow cytometry or elutriation of synchronized cells treated with actinomycin D1, camptothecin, or aphidicolin, each of which had been documented to exert its effects in a particular phase of the cell cycle. [5] Surprisingly, the authors found that each of the agents was able to induce apoptosis in all phases of the cell cycle, suggesting that the mechanism through which the drugs induce apoptosis may be independent of the drugs’ biochemical targets. [5] In fact, a trace through the literature on the S-phase specificity of cytarabine leads to studies that simply assume S-phase specificity based on cytarabine's reported site of biochemical action, [6] which the later papers reference. The lack of a cell cycle effect for camptothecin has also been reported recently in a live-cell microscopy study. [7]

Cell-to-cell variation in protein levels

A recent paper by Spencer et al. [8] raises the possibility that cell-to-cell variability in protein concentrations may contribute to fractional killing in the case of treatment with TRAIL (TNF-related apoptosis inducing ligand). TRAIL is a ligand native to the human body that is currently being developed as a cancer treatment. Spencer et al. observed fractional killing at a single cell level in several cell lines, even in genetically identical populations grown in homogeneous environments. This paper ruled out the conventional explanation (cell cycle effects) in two of these cell lines, and provided evidence supporting the hypothesis that random variation in cellular initial conditions causes some cells to die while allowing others to survive.

Related Research Articles

Chemotherapy Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent, or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

Experimental cancer treatments are non-medical therapies intended to treat cancer by improving on, supplementing or replacing conventional methods. Experimental cancer treatments cannot make medical claims. The term experimental cancer treatment could thus be substituted for "non FDA approved cancer treatment."

Cytarabine Chemical compound (chemotherapy medication)

Cytarabine, also known as cytosine arabinoside (ara-C), is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma. It is given by injection into a vein, under the skin, or into the cerebrospinal fluid. There is a liposomal formulation for which there is tentative evidence of better outcomes in lymphoma involving the meninges.

History of cancer chemotherapy

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

Daunorubicin

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically it is used for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. It is used by injection into a vein. A liposomal formulation known as liposomal daunorubicin also exists.

Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single and double stranded DNA breaks that they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.

PAC-1

This article refers to the anti-tumor molecule, and not the a2iib3 integrin activation specific antibody of the same name

Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.

Ixabepilone

Ixabepilone is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.

Hyper-CVAD is a chemotherapy regimen used to treat some forms of leukemia, high-grade non-Hodgkin lymphoma, and lymphoblastic leukemia.

Eribulin

Eribulin, sold under the brand name Halaven, is an anticancer medication used to treat breast cancer and liposarcoma.

Panobinostat

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor.

Gene expression profiling has revealed that diffuse large B-cell lymphoma (DLBCL) is composed of at least 3 different sub-groups, each having distinct oncogenic mechanisms that respond to therapies in different ways. Germinal Center B-Cell like (GCB) DLBCLs appear to arise from normal germinal center B cells, while Activated B-cell like (ABC) DLBCLs are thought to arise from postgerminal center B cells that are arrested during plasmacytic differentiation. The differences in gene expression between GCB DLBCL and ABC DLBCL are as vast as the differences between distinct types of leukemia, but these conditions have historically been grouped together and treated as the same disease.

Edelfosine is a synthetic alkyl-lysophospholipid (ALP). It has antineoplastic (anti-cancer) effects.

Volasertib

Volasertib is an experimental small molecule inhibitor of the PLK1 protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.

VAMP regimen or VAMP chemotherapy is a four-drug combination chemotherapy regimen, used today in the treatment of Hodgkin lymphoma. It was one of the earliest combination chemotherapy regimens, originally developed as a treatment for childhood leukemia by a group of researchers at the National Cancer Institute led by Emil Frei and Emil Freireich. The first clinical trial of VAMP began in 1961. Because it was the first time that four chemotherapeutic agents were used at once, the trial was highly controversial at its time. Although new combination chemotherapy regimens have replaced the use of VAMP in the treatment of childhood leukemia, VAMP is considered an important precursor to modern treatments, confirming the effectiveness of combination chemotherapy and leading to the use of combination chemotherapy regimens to treat other types of cancer.

Cytostasis is the inhibition of cell growth and multiplication. Cytostatic refers to a cellular component or medicine that inhibits cell division.

Micro-Culture Kinetic (MiCK) assay, developed by DiaTech Oncology, is a clinical pathology test that measures apoptosis induced in specific patient's cancer cells via chemotherapy. The assay is performed by DiaTech Oncology in its CLAI-certified, CAP-accredited laboratory. The MiCK assay provides oncologists with a clinically relevant drug-sensitivity profile of tumor cells of an individual cancer patient.

Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies. In some cases, cancers can evolve resistance to multiple drugs, called multiple drug resistance.

Venetoclax

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).

References

  1. ↑ Berenbaum, M. C. (1972). "In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents." Cancer Chemother Rep 56(5): 563-71.
  2. ↑ Skipper, H. E. (1979). "Historic milestones in cancer biology: a few that are important in cancer treatment (revisited)." Semin Oncol 6(4): 506-14.
  3. 1 2 3 4 5 6 Chabner, B. and D. L. Longo (2006). Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, Lippincott Willians & Wilkins.
  4. 1 2 3 4 5 6 Skeel, R. T. (2003). Handbook of Cancer Chemotherapy, Lippincott Williams & Wilkins.
  5. 1 2 3 Cotter, T. G., J. M. Glynn, et al. (1992). "The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle." Anticancer Res 12(3): 773-9.
  6. ↑ Skipper, H. E., F. M. Schabel, Jr., et al. (1970). "Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules." Cancer Chemother Rep 54(6): 431-50.
  7. ↑ Cohen, A. A., N. Geva-Zatorsky, et al. (2008). "Dynamic proteomics of individual cancer cells in response to a drug." Science 322(5907): 1511-6.
  8. ↑ Spencer, S. L., S. Gaudet, et al. (2009). "Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis." Nature. http://www.nature.com/nature/journal/vaop/ncurrent/full/nature08012.html.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.